Association Between 2-Dose vs 3-Dose Hepatitis B Vaccine and Acute Myocardial Infarction.

ABSTRACT:

Importance

The 2-dose hepatitis B vaccine with a cytosine phosphoguanine adjuvant (HepB-CpG vaccine; Heplisav-B) generated higher seroprotection in prelicensure trials than did a 3-dose hepatitis B vaccine with an aluminum hydroxide adjuvant (HepB-alum vaccine; Engerix-B). However, in 1 trial, a higher number of acute myocardial infarction (MI) events were observed among those who received the HepB-CpG vaccine than among those who received the HepB-alum vaccine, an outcome requiring further study.

Objective

To compare the rate of acute MI between recipients of HepB-CpG vaccine and HepB-alum vaccine.

Design, setting, and participants

This prospective cohort noninferiority study was conducted at Kaiser Permanente Southern California (KPSC), an integrated health care sys

SUBMITTER: Bruxvoort K 

PROVIDER: S-EPMC8957040 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature